Cancer Advisor

Understanding PET scan responses, tumor biology, and how “metabolic response” has become a key cancer treatment endpoint Introduction In modern oncology, treatment success is no longer judged only by whether a tumor shrinks on a CT scan. A deeper concept has become increasingly important: Metabolic response — the change in cancer cell activity, not just tumor size. This shift comes from advances in PET imaging , which can detect cancer activity at a cellular energy level long before anatomical changes appear. Understanding metabolic response is essential for interpreting: Chemotherapy outcomes Immunotherapy results Targeted therapy effectiveness And even controversial or experimental treatment reports. What Is Metabolic Response in Cancer? A metabolic response refers to changes in how active cancer cells are, typically measured using a PET (Positron Emission Tomography) scan . Most commonly, PET scans use a tracer called FDG (fluorodeoxyglucose) , a radioactive form of glucose. Cancer...

Daraxonrasib (RMC-6236) nearly doubles median survival in previously treated metastatic pancreatic cancer (13.2 vs. 6.7 months) with a 60% reduction in death risk. Learn about the breakthrough RAS(ON) inhibitor, side effects, trial results, cost concerns, and what it means for patients in 2026. Pancreatic cancer remains one of the deadliest cancers, with a 5-year survival rate under 13% overall and just 3% for metastatic disease. But in May 2026, a new oral pill called daraxonrasib (also known as RMC-6236) delivered what experts are calling “historic” and “practice-changing” results.In the pivotal Phase 3 RASolute 302 trial, daraxonrasib doubled median overall survival and cut the risk of death by 60% compared to standard chemotherapy — all while being better tolerated for many patients.  Here’s everything you need to know about this groundbreaking pancreatic cancer treatment, including the science, real-world implications, side effects, cost debates, and expert perspectives. What ...